For: | Pramanik S, Pal P, Ray S. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies. World J Methodol 2024; 14(2): 91319 [PMID: 38983664 DOI: 10.5662/wjm.v14.i2.91319] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v14/i2/91319.htm |
Number | Citing Articles |
1 |
Hisayuki Katsuyama, Seiichi Horinaka, Mariko Hakoshima, Hiroki Adachi, Hidekatsu Yanai. Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients. Journal of Clinical Medicine 2024; 13(16): 4929 doi: 10.3390/jcm13164929
|
2 |
Nawfal Hasan Siam, Nayla Nuren Snigdha, Noushin Tabasumma, Irin Parvin. Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies. Reviews in Cardiovascular Medicine 2024; 25(12) doi: 10.31083/j.rcm2512436
|
3 |
Marcio J Concepción-Zavaleta, Jenyfer M Fuentes-Mendoza, Jhean G Gonzáles-Yovera, Gemma Y Ruvalcaba-Barbosa, Leonardo D Cura-Rodríguez, Josué S González-Rodríguez, Luis A Concepción-Urteaga, Aranza I Pérez-Reyes, Juan Eduardo Quiroz-Aldave, José Paz-Ibarra. Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. World Journal of Gastroenterology 2025; 31(37): 111435 doi: 10.3748/wjg.v31.i37.111435
|